

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	LICENSE
CONVEYING PARTY DATA	
Name	Execution Date
Plethora Solutions Limited	03/27/2008
RECEIVING PARTY DATA	
Name:	Plethora Therapeutics Limited
Street Address:	Lupus House
Internal Address:	11-13 Macklin Street Covent Garden
City:	London
State/Country:	UNITED KINGDOM
Postal Code:	WC2B 5NH
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	5354287
CORRESPONDENCE DATA	
Fax Number:	(312)277-2397
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	3125777000
Email:	LBultema@fitcheven.com
Correspondent Name:	Fitch, Even, Tabin & Flannery
Address Line 1:	120 S. LaSalle Street
Address Line 2:	Suite 1600
Address Line 4:	Chicago, ILLINOIS 60603
NAME OF SUBMITTER:	Richard A. Kaba
Total Attachments: 4 source=Novation Agreement.doc#page1.tif source=Novation Agreement.doc#page2.tif source=Novation Agreement.doc#page3.tif source=Novation Agreement.doc#page4.tif	

CH \$40.00 5354287

NOVATION AGREEMENT

BETWEEN:

Plethora Solutions Limited (Company No 04977609) a company existing under the laws of England and Wales and having its Registered Office address at Lupus House, 11-13 Macklin Street Covent Garden, London WC2B 5NH (hereinafter called "**Solutions**") of the one part; and

Plethora Therapeutics Limited (Company No 06541644) a company existing under the laws of England and Wales and having its Registered Office address at Lupus House, 11-13 Macklin Street Covent Garden, London WC2B 5NH hereinafter called "**Therapeutics**") of the second part;

WHEREAS

- (A) Senetek plc and Solutions are parties to a licence agreement, (as amended by the Amendment Agreement of 26 March 2008) (hereinafter referred to as the "Amended Senetek Licence"); and
- (B) Solutions wishes to novate its entire interest in the Amended Senetek Licence in favour of Therapeutics; and
- (C) Solutions has agreed to novate its entire interest as licensee of the Amended Senetek Licence, and Therapeutics has agreed to accept the novation in its favour as licensee of the entire interest, duties, obligations, burdens benefits and rights in the Amended Senetek Licence on the terms and conditions set out in this Agreement.

NOW THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

1. DEFINITIONS

Senetek Licence means the licence executed by Senetek plc on 16 February 2006 and Plethora Solutions Limited on 14 February 2006.

Amendment Agreement means the Amendment Agreement executed by Senetek plc, Solutions, Holdings and Therapeutics on 26 March 2008.

Amended Senetek Licence means the Senetek Licence as amended by the Amendment Agreement executed by Senetek plc, Solutions, Holdings and Therapeutics on 26 March 2008.

Intragroup Asset Transfer Agreement means the agreement executed on 27 March 2008 by Plethora Solutions Limited and by Plethora Therapeutics Limited.

Intellectual Property Rights mean Intellectual Property Rights as defined in the Senetek Licence.

2. NOVATION

2.1 Pursuant to the provisions of Clause 5.1 of the Senetek Licence, and Clause 5.2 of the Amendment Agreement, Solutions shall hereby novate its entire interest in the Senetek Licence to Therapeutics, and Therapeutics shall observe, comply with, and be bound by all of the obligations undertaken by Solutions in the Senetek Licence, and shall enjoy all of the benefits granted to Solutions under the Senetek Licence including but not limited to the patents and trade marks short particulars of which are set out in Schedule One attached hereto.

2.2 Without prejudice to the generality of the foregoing, Therapeutics shall be entitled to all of the benefit of, and to do all such acts that Solutions was entitled

and/or obligated to do under the Senetek Licence in respect of all of the Intellectual Property Rights licensed to Solutions under the Senetek Licence, including but not limited to the benefit of the patents and trade marks listed in Parts 1(a), 1(b), 2(a) and 2(b) of the schedule to the Senetek Licence.

2.3 This Novation Agreement has retrospective effect from 27 March 2008.

3. SCHEDULE ONE

Product Patents

Country	Status	Patent No	Expiration Date	Renewal Date
United States	Granted	5236904	17 August 2013	
United States	Granted	5447912	5 September 2015	
Canada	Granted	2065270	14 September 2010	15 September 2008

Delivery System Patents

Country	Status	Patent No	Expiration Date	Renewal Date
United States	Granted	5354287	10 November 2014	
Canada	Granted	2125179	30 September 2013	15 September 2008
United States	Granted	5709668	10 November 2014	20 July 2009

(Term can be no greater than US5354287).

Trade Marks

Country	Trade Mark	Status	Trade Mark No	Renewal Date
United States	INVICORP	Granted	2537523	12 February 2012
United States	RELIAJECT	Pending	78/516916	
United States	RELIAJECT	Pending	76/340162	
Canada	RELIAJECT	Granted	896991	
Canada	RELIAJECT	Pending	1380885	

IN WITNESS WHEREOF these presents are executed in duplicate

For and on behalf of Plethora Solutions Limited

Signed by MG Willie

on this 30 day of June 2008

MG WILLIE (Full Name)

Donald Lawrie (Witness)

DONALD LAWRIE (Witness)

For and on behalf of Plethora Therapeutics Limited

Signed by MG Willie

on this 30 day of June 2008

MG WILLIE (Full Name)

Donald Lawrie (Witness)

DONALD LAWRIE (Witness)